Enterprise Value

29.63M

Cash

37.5M

Avg Qtr Burn

-5.119M

Short % of Float

0.37%

Insider Ownership

9.92%

Institutional Own.

48.96%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
NX-13 Details
Ulcerative colitis

Phase 2

Data readout

Omilancor Details
Eosinophilic Esophagitis

Failed

Discontinued

Failed

Discontinued

LABP-104 Details
Rheumatoid arthritis

Failed

Discontinued

Failed

Discontinued

LABP-104 Details
Systemic lupus erythematosus

Failed

Discontinued

NX-13 Details
Crohns disease

Failed

Discontinued

Omilancor (BT-11) Details
Ulcerative colitis

Failed

Discontinued